Becton Dickinson and Clontech, Beckman Coulter, Addex Pharmaceuticals and Ortho-McNeil, Ambit Biosciences and Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer, and Albany Molecular Research and Alcon Research

Jan 18, 2005

Premium

Becton Dickinson to Sell Clontech in Q2 or Q3, Official Says; Buyer Remains Undisclosed

Becton Dickinson expects to complete the sale of its Clontech division in the second or third quarter, the company said last week.

“The process is moving ahead according to schedule,” Vince Forlenza, president of BD Biosciences, said at the JPMorgan Healthcare Conference, held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu